120 related articles for article (PubMed ID: 37683591)
1. Antitumor activity of alkylphospholipid edelfosine in prostate cancer models and endoplasmic reticulum targeting.
Dakir EH; Gajate C; Mollinedo F
Biomed Pharmacother; 2023 Nov; 167():115436. PubMed ID: 37683591
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine.
Bonilla X; Dakir el-H; Mollinedo F; Gajate C
Oncotarget; 2015 Jun; 6(16):14596-613. PubMed ID: 25999349
[TBL] [Abstract][Full Text] [Related]
3. Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition.
Gajate C; Gayet O; Fraunhoffer NA; Iovanna J; Dusetti N; Mollinedo F
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885233
[TBL] [Abstract][Full Text] [Related]
4. Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine.
Alonso-Pérez V; Hernández V; Calzado MA; Vicente-Blázquez A; Gajate C; Soler-Torronteras R; DeCicco-Skinner K; Sierra A; Mollinedo F
Biomed Pharmacother; 2024 Feb; 171():116149. PubMed ID: 38266621
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Targeting Involving Cholesterol-Rich Lipid Rafts in the Mechanism of Action of the Antitumor Ether Lipid and Alkylphospholipid Analog Edelfosine.
Mollinedo F; Gajate C
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34065546
[TBL] [Abstract][Full Text] [Related]
6. Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.
Gajate C; Mollinedo F
Anticancer Agents Med Chem; 2014 May; 14(4):509-27. PubMed ID: 24628241
[TBL] [Abstract][Full Text] [Related]
7. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.
Gajate C; Matos-da-Silva M; Dakir el-H; Fonteriz RI; Alvarez J; Mollinedo F
Oncogene; 2012 May; 31(21):2627-39. PubMed ID: 22056873
[TBL] [Abstract][Full Text] [Related]
8. Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer.
Mollinedo F; Gajate C
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439330
[TBL] [Abstract][Full Text] [Related]
9. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.
Udayakumar TS; Stoyanova R; Shareef MM; Mu Z; Philip S; Burnstein KL; Pollack A
Mol Cancer Ther; 2016 Jun; 15(6):1353-63. PubMed ID: 26944919
[TBL] [Abstract][Full Text] [Related]
10. ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells.
Melo-Lima S; Lopes MC; Mollinedo F
Pharmacol Res; 2015; 95-96():2-11. PubMed ID: 25749008
[TBL] [Abstract][Full Text] [Related]
11. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.
Villa-Pulgarín JA; Gajate C; Botet J; Jimenez A; Justies N; Varela-M RE; Cuesta-Marbán Á; Müller I; Modolell M; Revuelta JL; Mollinedo F
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005805. PubMed ID: 28829771
[TBL] [Abstract][Full Text] [Related]
12. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine.
Yepes E; Varela-M RE; López-Abán J; Dakir el H; Mollinedo F; Muro A
PLoS One; 2014; 9(10):e109431. PubMed ID: 25302497
[TBL] [Abstract][Full Text] [Related]
14. Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells.
Nieto-Miguel T; Fonteriz RI; Vay L; Gajate C; López-Hernández S; Mollinedo F
Cancer Res; 2007 Nov; 67(21):10368-78. PubMed ID: 17974980
[TBL] [Abstract][Full Text] [Related]
15. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
16. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells.
Nieto-Miguel T; Gajate C; Mollinedo F
J Biol Chem; 2006 May; 281(21):14833-40. PubMed ID: 16540473
[TBL] [Abstract][Full Text] [Related]
17. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
18. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
[TBL] [Abstract][Full Text] [Related]
19. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
20. The ethanol extract of Cyperus exaltatus var. iwasakii exhibits cell cycle dysregulation, ERK1/2/p38 MAPK/AKT phosphorylation, and reduced MMP-9-mediated metastatic capacity in prostate cancer models in vitro and in vivo.
Kim H; Hwang B; Cho S; Kim WJ; Myung SC; Choi YH; Kim WJ; Lee S; Moon SK
Phytomedicine; 2023 Jun; 114():154794. PubMed ID: 37011419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
